Enter your contact details & our Business Development
expert will circle back to address your request!
Auguest 18, 2021, New York, USA - Plasma is the protein-rich fluid that differentiates the cells in the human body and helps the body achieve transport functions. It is a mixture of different proteins called the Lippo proteins and other conjugated proteins. It is an important biological medicine that treats the rarest of diseases. The proteins which are found in the plasma have an important function to perform and that is of clotting and providing the required immunity to various diseases. The plasma proteins are also used in various other functions such as shocks and various high-level burns, along with any kind of bleeding disorders and autoimmune deficiencies.
The Plasma protein therapies are used to treat various chronic disorders, severe life-threatening and major illnesses along with treating various genetic disorders. The plasma protein has a unique biochemical which treats the body with a biochemical profile. It differs in the processing methods and the way of the production process.
Plasma is that liquid part of the blood which gives the residue once the platelets, the red blood cells, and the other cellular parts of the body then get detached. The plasma is the largest and the important system in the human body which provides healthy proteins, salts, water, and the enzymes essential for the functioning of the body.
The overview of the Plasma Protein Market-
The Global Plasma Protein Therapeutics Market is expected to grow at a rate of 5.06% CAGR from 2021 to 2025. It is also expected to show a growth forecast of $US22663 million during the period from 2021-2025.
North America is expected to be the leading country globally in the Plasma Protein Therapeutics market. The reason for the rise in some growth factors namely an increase in the rise of auto-immune diseases and various neurological diseases; So overall the United States is expected to be the largest market for this domain.
In the United States, another cause of disability among adults is the rising cause of arthritis and this is also another major reason for the demand for the global plasma protein therapeutics market. Statistics say that there were about 54 million people who suffered from this condition and the majority of them were adults, also around 300,000 children alone in the United States suffered from some sort of a rheumatic condition.
After North America, Europe is expected to dominate the market and with approximately 70% of the market share, along with the presence of a large patient base. The other reasons are well-developed infrastructure; the availability of high-quality presence of plasma and increased adoption of innovative techniques have driven the growth of the market in the European region.
The Asia-Pacific is expected to provide the largest CAGR growth, while China ranks first in the usage of the albumin market. The other factors which are contributing to the growth in the Asia-Pacific region are the advanced level of treatments, the developing economies, and the increasing per capita income which is anticipated to open up increasing avenues for the markets in Asia-Pacific.
The Albumin segment in the Plasma proteins is expected to be the highest during the forecast period. The diseases responsible for it are Hemophilia which is the bleeding of the blood from the different parts of the body. It prevents the normal clotting of the blood and the amount of the blood loss depends on the severity of the disease. The increasing rise of Hemophilia and the huge patient market is expected to be the biggest trigger during the forecast period.
Plasma Protein therapy is also expected to boost the market along with Hepatitis B being a major driving factor.
The growth opportunities in the plasma protein market also lie in the availability of pharmaceuticals that are used to treat various diseases.
Also, there has been an increasing level of research and development going on in this domain which is expected to boost the market segment.
Some of the top companies in this market include-
The market is likely to remain competitive in the forecast period with new companies entering the market and focusing on innovation and expanding plasma collection networks.
Some of the recent developments in the Global Plasma Protein market include-
Biotest was the first protein manufacturer which was the first ever to develop an investigational hyperimmune globin in the preparation against Covid 19.
In July 2020, Grifols signed an agreement with GC Pharma to acquire its Montreal-based plasma fractionation facility.
The Plasma Protein is however not immune from certain restraining factors such as
There have been highly stringent government policies
There have been several issues about the reimbursement methods
There have been several issues in the area of manufacturing.
The growing need of the increasing population coupled with new and improved innovation is going to give a big boost to the Global Plasma Protein Therapeutics market.
Please fill form below: